Key Takeaways REPL gained on FDA acceptance of its resubmitted BLA for RP1 with Opdivo in advanced melanoma.FDA confirmed the resubmission addresses prior CRL issues, with a final approval decision due April 10, 2026.Replimune reported a 44% response rate and 11.9-month median response in acral melanoma from the IGNYTE study.Shares of Replimune Group (REPL) have surged 131.1% over the past three months, fueled by positive regulatory updates.In October, the FDA accepted the resubmission of the biologics lice ...